Literature DB >> 25896705

Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital.

Brunella Posteraro1, Teresa Spanu2, Barbara Fiori2, Flavio De Maio2, Elena De Carolis2, Alessia Giaquinto2, Valentina Prete2, Giulia De Angelis2, Riccardo Torelli2, Tiziana D'Inzeo2, Antonietta Vella2, Alessio De Luca3, Mario Tumbarello4, Walter Ricciardi1, Maurizio Sanguinetti5.   

Abstract

Sensititre YeastOne (SYO) is an affordable alternative to the Clinical and Laboratory Standards Institute (CLSI) reference method for antifungal susceptibility testing. In this study, the MICs of yeast isolates from 1,214 bloodstream infection episodes, generated by SYO during hospital laboratory activity (January 2005 to December 2013), were reanalyzed using current CLSI clinical breakpoints/epidemiological cutoff values to assign susceptibility (or the wild-type [WT] phenotype) to systemic antifungal agents. Excluding Candida albicans (57.4% of all isolates [n = 1,250]), the most predominant species were Candida parapsilosis complex (20.9%), Candida tropicalis (8.2%), Candida glabrata (6.4%), Candida guilliermondii (1.6%), and Candida krusei (1.3%). Among the non-Candida species (1.9%), 7 were Cryptococcus neoformans and 17 were other species, mainly Rhodotorula species. Over 97% of Candida isolates were susceptible (WT phenotype) to amphotericin B and flucytosine. Rates of susceptibility (WT phenotype) to fluconazole, itraconazole, and voriconazole were 98.7% in C. albicans, 92.3% in the C. parapsilosis complex, 96.1% in C. tropicalis, 92.5% in C. glabrata, 100% in C. guilliermondii, and 100% (excluding fluconazole) in C. krusei. The fluconazole-resistant isolates consisted of 6 C. parapsilosis complex isolates, 3 C. glabrata isolates, 2 C. albicans isolates, 2 C. tropicalis isolates, and 1 Candida lusitaniae isolate. Of the non-Candida isolates, 2 C. neoformans isolates had the non-WT phenotype for susceptibility to fluconazole, whereas Rhodotorula isolates had elevated azole MICs. Overall, 99.7% to 99.8% of Candida isolates were susceptible (WT phenotype) to echinocandins, but 3 isolates were nonsusceptible (either intermediate or resistant) to caspofungin (C. albicans, C. guilliermondii, and C. krusei), anidulafungin (C. albicans and C. guilliermondii), and micafungin (C. albicans). However, when the intrinsically resistant non-Candida isolates were included, the rate of echinocandin nonsusceptibility reached 1.8%. In summary, the SYO method proved to be able to detect yeast species showing antifungal resistance or reduced susceptibility.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25896705      PMCID: PMC4468684          DOI: 10.1128/AAC.00285-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  49 in total

1.  Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?

Authors:  A Espinel-Ingroff; M C Arendrup; M A Pfaller; L X Bonfietti; B Bustamante; E Canton; E Chryssanthou; M Cuenca-Estrella; E Dannaoui; A Fothergill; J Fuller; P Gaustad; G M Gonzalez; J Guarro; C Lass-Flörl; S R Lockhart; J F Meis; C B Moore; L Ostrosky-Zeichner; T Pelaez; S R B S Pukinskas; G St-Germain; M W Szeszs; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

2.  Comparison of the Vitek 2 antifungal susceptibility system with the clinical and laboratory standards institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) Broth Microdilution Reference Methods and with the Sensititre YeastOne and Etest techniques for in vitro detection of antifungal resistance in yeast isolates.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Ana Alastruey-Izquierdo; Leticia Bernal-Martinez; Isabel Cuesta; Maria J Buitrago; Juan L Rodriguez-Tudela
Journal:  J Clin Microbiol       Date:  2010-03-10       Impact factor: 5.948

3.  Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria.

Authors:  Michael A Pfaller; Shawn A Messer; Daniel J Diekema; Ronald N Jones; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2013-10-23       Impact factor: 5.948

4.  Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.

Authors:  Barbara D Alexander; Melissa D Johnson; Christopher D Pfeiffer; Cristina Jiménez-Ortigosa; Jelena Catania; Rachel Booker; Mariana Castanheira; Shawn A Messer; David S Perlin; Michael A Pfaller
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

5.  Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011.

Authors:  Jesús Guinea; Óscar Zaragoza; Pilar Escribano; Estrella Martín-Mazuelos; Javier Pemán; Ferrán Sánchez-Reus; Manuel Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

6.  Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme.

Authors:  M C Arendrup; E Dzajic; R H Jensen; H K Johansen; P Kjaeldgaard; J D Knudsen; L Kristensen; C Leitz; L E Lemming; L Nielsen; B Olesen; F S Rosenvinge; B L Røder; H C Schønheyder
Journal:  Clin Microbiol Infect       Date:  2013-04-22       Impact factor: 8.067

7.  Epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole for six Candida species as determined by the colorimetric Sensititre YeastOne method.

Authors:  Emilia Cantón; Javier Pemán; Carmen Iñiguez; David Hervás; Jose L Lopez-Hontangas; Cidalia Pina-Vaz; Juan J Camarena; Isolina Campos-Herrero; Inmaculada García-García; Ana M García-Tapia; Remedios Guna; Paloma Merino; Luisa Pérez del Molino; Carmen Rubio; Anabel Suárez
Journal:  J Clin Microbiol       Date:  2013-06-12       Impact factor: 5.948

8.  Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.

Authors:  Michael A Pfaller; Shawn A Messer; Leah N Woosley; Ronald N Jones; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2013-05-29       Impact factor: 5.948

9.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT).

Authors:  A J Ullmann; M Akova; R Herbrecht; C Viscoli; M C Arendrup; S Arikan-Akdagli; M Bassetti; J Bille; T Calandra; E Castagnola; O A Cornely; J P Donnelly; J Garbino; A H Groll; W W Hope; H E Jensen; B J Kullberg; C Lass-Flörl; O Lortholary; W Meersseman; G Petrikkos; M D Richardson; E Roilides; P E Verweij; M Cuenca-Estrella
Journal:  Clin Microbiol Infect       Date:  2012-12       Impact factor: 8.067

10.  ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections.

Authors:  M C Arendrup; T Boekhout; M Akova; J F Meis; O A Cornely; O Lortholary
Journal:  Clin Microbiol Infect       Date:  2014-04       Impact factor: 8.067

View more
  27 in total

1.  Epidemiological Trends of Fungemia in Greece with a Focus on Candidemia during the Recent Financial Crisis: a 10-Year Survey in a Tertiary Care Academic Hospital and Review of Literature.

Authors:  Maria Siopi; Aikaterini Tarpatzi; Eleni Kalogeropoulou; Sofia Damianidou; Alexandra Vasilakopoulou; Sophia Vourli; Spyros Pournaras; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

2.  Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method.

Authors:  A Espinel-Ingroff; M Arendrup; E Cantón; S Cordoba; E Dannaoui; J García-Rodríguez; G M Gonzalez; N P Govender; E Martin-Mazuelos; M Lackner; C Lass-Flörl; M J Linares Sicilia; M A Rodriguez-Iglesias; T Pelaez; R K Shields; G Garcia-Effron; J Guinea; M Sanguinetti; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

3.  Evaluation of Two Commercial Broth Microdilution Methods Using Different Interpretive Criteria for the Detection of Molecular Mechanisms of Acquired Azole and Echinocandin Resistance in Four Common Candida Species.

Authors:  Ha Jin Lim; Jong Hee Shin; Mi-Na Kim; Dongeun Yong; Seung A Byun; Min Ji Choi; Seung Yeob Lee; Eun Jeong Won; Seung-Jung Kee; Soo Hyun Kim; Myung-Geun Shin
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

4.  Invasive Candidiasis in Brescia, Italy: Analysis of Species Distribution and Antifungal Susceptibilities During Seven Years.

Authors:  M A De Francesco; G Piccinelli; M Gelmi; F Gargiulo; G Ravizzola; G Pinsi; L Peroni; C Bonfanti; A Caruso
Journal:  Mycopathologia       Date:  2017-06-08       Impact factor: 2.574

5.  Susceptibility Testing of Common and Uncommon Aspergillus Species against Posaconazole and Other Mold-Active Antifungal Azoles Using the Sensititre Method.

Authors:  Enrica Mello; Brunella Posteraro; Antonietta Vella; Elena De Carolis; Riccardo Torelli; Tiziana D'Inzeo; Paul E Verweij; Maurizio Sanguinetti
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

6.  Multicenter study of epidemiological cutoff values and detection of resistance in Candida spp. to anidulafungin, caspofungin, and micafungin using the Sensititre YeastOne colorimetric method.

Authors:  A Espinel-Ingroff; M Alvarez-Fernandez; E Cantón; P L Carver; S C-A Chen; G Eschenauer; D L Getsinger; G M Gonzalez; N P Govender; A Grancini; K E Hanson; S E Kidd; K Klinker; C J Kubin; J V Kus; S R Lockhart; J Meletiadis; A J Morris; T Pelaez; G Quindós; M Rodriguez-Iglesias; F Sánchez-Reus; S Shoham; N L Wengenack; N Borrell Solé; J Echeverria; J Esperalba; E Gómez-G de la Pedrosa; I García García; M J Linares; F Marco; P Merino; J Pemán; L Pérez Del Molino; E Roselló Mayans; C Rubio Calvo; M Ruiz Pérez de Pipaon; G Yagüe; G Garcia-Effron; J Guinea; D S Perlin; M Sanguinetti; R Shields; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

7.  Epidemiology, clinical characteristics, and outcome of candidemia in a tertiary referral center in Italy from 2010 to 2014.

Authors:  Francesco Barchiesi; Elena Orsetti; Rosaria Gesuita; Edlira Skrami; Esther Manso
Journal:  Infection       Date:  2015-09-26       Impact factor: 3.553

8.  Antifungal Susceptibility of Clinical Yeast Isolates from a Large Canadian Reference Laboratory and Application of Whole-Genome Sequence Analysis To Elucidate Mechanisms of Acquired Resistance.

Authors:  Lisa R McTaggart; Ana Cabrera; Kirby Cronin; Julianne V Kus
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

9.  Direct Fluconazole Disk Susceptibility Testing for Candida glabrata-Positive Blood Cultures.

Authors:  Sarah Israel; Amichai Perlman; Jacob Moran-Gilad; Maya Korem
Journal:  J Clin Microbiol       Date:  2021-06-18       Impact factor: 5.948

Review 10.  Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis.

Authors:  Haiying Jin; Tiansheng Wang; Bonnie A Falcione; Keith M Olsen; Ken Chen; Huilin Tang; John Hui; Suodi Zhai
Journal:  J Antimicrob Chemother       Date:  2016-03-10       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.